- Home
- SNEX vs INAB Comparison
SNEX vs INAB Comparison
Compare SNEX & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNEX
- INAB
- Stock Information
- Founded
- SNEX 1924
- INAB 2016
- Country
- SNEX United States
- INAB United States
- Employees
- SNEX N/A
- INAB N/A
- Industry
- SNEX Investment Bankers/Brokers/Service
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- SNEX Finance
- INAB Health Care
- Exchange
- SNEX Nasdaq
- INAB Nasdaq
- Market Cap
- SNEX 3.3B
- INAB 24.0M
- IPO Year
- SNEX 1994
- INAB 2021
- Fundamental
- Price
- SNEX $94.66
- INAB $0.25
- Analyst Decision
- SNEX
- INAB Strong Buy
- Analyst Count
- SNEX 0
- INAB 3
- Target Price
- SNEX N/A
- INAB $7.75
- AVG Volume (30 Days)
- SNEX 173.7K
- INAB 727.4K
- Earning Date
- SNEX 02-04-2025
- INAB 11-12-2024
- Dividend Yield
- SNEX N/A
- INAB N/A
- EPS Growth
- SNEX 6.85
- INAB N/A
- EPS
- SNEX 7.96
- INAB N/A
- Revenue
- SNEX $98,704,300,000.00
- INAB N/A
- Revenue This Year
- SNEX N/A
- INAB N/A
- Revenue Next Year
- SNEX N/A
- INAB N/A
- P/E Ratio
- SNEX $11.94
- INAB N/A
- Revenue Growth
- SNEX 64.52
- INAB N/A
- 52 Week Low
- SNEX $61.68
- INAB $0.22
- 52 Week High
- SNEX $106.77
- INAB $1.93
- Technical
- Relative Strength Index (RSI)
- SNEX 37.96
- INAB 39.26
- Support Level
- SNEX $90.87
- INAB $0.28
- Resistance Level
- SNEX $103.92
- INAB $0.32
- Average True Range (ATR)
- SNEX 2.49
- INAB 0.03
- MACD
- SNEX -1.61
- INAB -0.01
- Stochastic Oscillator
- SNEX 21.42
- INAB 13.73
About SNEX StoneX Group Inc.
StoneX Group Inc is a Global brokerage and financial services firm. Its service offerings are execution, OTC / Market-Making, advisory services, Global payment solutions, market intelligence, Physical Trading and clearing services. The firm operates in four segments: commercial, Institutional, Retail, and Global Payments. Its customers include governmental and nongovernmental organizations, and commercial banks, brokers, institutional investors, and investment banks. The company operates in United States, South America, Europe, Middle East and Asia and other countries, out of which majority revenue is generates from Middle East and Asia Region.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.